Pharma reshoring sparks talent war for manufacturing roles
Pharmaceutical companies are competing for manufacturing talent as they reshore production to the U.S., according to industry experts. CAI CEO Sheena Dempsey says the competition will intensify in 2027-2028, with data centers also hiring for similar roles. A 2026 report warns that only a few regions have enough skilled workers to support large biologics facilities.
The scale of announced investment is substantial, with major pharmaceutical firms committing over $160 billion collectively to U.S. production sites across states like Texas, Indiana, and North Carolina. These facilities are projected to require thousands of workers, from engineers to quality assurance specialists. Industry surveys indicate persistent hiring difficulties, with more than a third of facilities unable to recruit process development staff and roughly a quarter lacking sufficient process engineers.
Regional workforce gaps are particularly acute. A 2026 analysis found that only a handful of U.S. regions possess enough skilled labor to support large biologics plants. In Indiana alone, projections suggest a need for up to 3,700 new biomanufacturing workers. Meanwhile, data center construction in states like Texas is drawing from the same labor pool, intensifying competition across all organizational levels.
This talent crunch could slow the pace of pharmaceutical reshoring, potentially delaying access to domestically produced medicines. Communities hosting new facilities may see job creation and economic benefits, but smaller regions could struggle to fill positions, forcing companies to recruit nationally or train workers from scratch. Patients may ultimately face fewer supply chain disruptions, though near-term production timelines could slip as employers compete for scarce skilled labor.